$0.06 EPS Expected for NeoGenomics, Inc. (NASDAQ:NEO) This Quarter

Share on StockTwits

Brokerages expect NeoGenomics, Inc. (NASDAQ:NEO) to post $0.06 earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for NeoGenomics’ earnings, with the lowest EPS estimate coming in at $0.05 and the highest estimate coming in at $0.07. NeoGenomics reported earnings per share of $0.05 in the same quarter last year, which would suggest a positive year-over-year growth rate of 20%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, October 29th.

According to Zacks, analysts expect that NeoGenomics will report full year earnings of $0.26 per share for the current year, with EPS estimates ranging from $0.24 to $0.28. For the next year, analysts anticipate that the business will post earnings of $0.34 per share, with EPS estimates ranging from $0.32 to $0.35. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for NeoGenomics.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, July 30th. The medical research company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.05 by $0.02. The company had revenue of $101.71 million during the quarter, compared to analysts’ expectations of $97.32 million. NeoGenomics had a net margin of 0.57% and a return on equity of 4.97%. The business’s revenue for the quarter was up 50.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.05 EPS.

A number of analysts recently commented on the stock. Leerink Swann set a $30.00 price objective on shares of NeoGenomics and gave the company a “buy” rating in a research report on Wednesday, July 31st. Zacks Investment Research cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Needham & Company LLC set a $27.00 target price on NeoGenomics and gave the stock a “buy” rating in a report on Wednesday, July 31st. Raymond James increased their target price on NeoGenomics from $23.00 to $27.00 and gave the stock an “outperform” rating in a report on Wednesday, July 31st. Finally, ValuEngine cut NeoGenomics from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $23.78.

Hedge funds have recently added to or reduced their stakes in the business. NEXT Financial Group Inc increased its holdings in NeoGenomics by 200.0% during the 2nd quarter. NEXT Financial Group Inc now owns 2,700 shares of the medical research company’s stock worth $59,000 after purchasing an additional 1,800 shares in the last quarter. Captrust Financial Advisors bought a new position in NeoGenomics during the 2nd quarter worth about $66,000. Winslow Evans & Crocker Inc. bought a new position in NeoGenomics during the 2nd quarter worth about $92,000. Oregon Public Employees Retirement Fund bought a new position in NeoGenomics during the 1st quarter worth about $132,000. Finally, Mark Sheptoff Financial Planning LLC acquired a new position in shares of NeoGenomics during the 1st quarter worth about $141,000. Hedge funds and other institutional investors own 83.06% of the company’s stock.

NEO opened at $24.45 on Friday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 4.52 and a current ratio of 4.67. NeoGenomics has a 12 month low of $11.05 and a 12 month high of $26.81. The company has a fifty day moving average price of $23.64. The company has a market cap of $2.57 billion, a PE ratio of 188.08 and a beta of 0.96.

NeoGenomics Company Profile

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Featured Article: What does a market perform rating mean?

Get a free copy of the Zacks research report on NeoGenomics (NEO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.